Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Increased detection of the HIV‐1 reverse transcriptase M184V mutation using mutation‐specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance

Increased detection of the HIV‐1 reverse transcriptase M184V mutation using mutation‐specific... Objectives The aim of the study was to estimate the levels of transmitted drug resistance (TDR) in HIV‐1 using very sensitive assays to detect minority drug‐resistant populations. Methods We tested unlinked anonymous serum specimens from sexual health clinic attendees, who had not received an HIV diagnosis at the time of sampling, by both standard genotyping and using minority detection assays. Results By standard genotyping, 21 of 165 specimens (12.7%) showed evidence of drug resistance, while, using a combination of standard genotyping and minority mutation assays targeting three commonly observed drug resistance mutations which cause high‐level resistance to commonly prescribed first‐line antiretroviral therapy (ART), this rose to 32 of 165 (19.4%). This increase of 45% in drug resistance levels (95% confidence interval (CI) 15.2–83.7%; P=0.002) was statistically significant. Almost all of this increase was accounted for by additional detections of the M184V mutation. Conclusions Future surveillance studies of TDR in the United Kingdom should consider combining standard genotyping and minority‐specific assays to provide more accurate estimates, particularly when using specimens collected from chronic HIV infections in which TDR variants may have declined to low levels. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Hiv Medicine Wiley

Increased detection of the HIV‐1 reverse transcriptase M184V mutation using mutation‐specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance

Loading next page...
 
/lp/wiley/increased-detection-of-the-hiv-1-reverse-transcriptase-m184v-mutation-V4h6LFSwKB

References (23)

Publisher
Wiley
Copyright
© 2010 British HIV Association
ISSN
1464-2662
eISSN
1468-1293
DOI
10.1111/j.1468-1293.2010.00882.x
pmid
21371237
Publisher site
See Article on Publisher Site

Abstract

Objectives The aim of the study was to estimate the levels of transmitted drug resistance (TDR) in HIV‐1 using very sensitive assays to detect minority drug‐resistant populations. Methods We tested unlinked anonymous serum specimens from sexual health clinic attendees, who had not received an HIV diagnosis at the time of sampling, by both standard genotyping and using minority detection assays. Results By standard genotyping, 21 of 165 specimens (12.7%) showed evidence of drug resistance, while, using a combination of standard genotyping and minority mutation assays targeting three commonly observed drug resistance mutations which cause high‐level resistance to commonly prescribed first‐line antiretroviral therapy (ART), this rose to 32 of 165 (19.4%). This increase of 45% in drug resistance levels (95% confidence interval (CI) 15.2–83.7%; P=0.002) was statistically significant. Almost all of this increase was accounted for by additional detections of the M184V mutation. Conclusions Future surveillance studies of TDR in the United Kingdom should consider combining standard genotyping and minority‐specific assays to provide more accurate estimates, particularly when using specimens collected from chronic HIV infections in which TDR variants may have declined to low levels.

Journal

Hiv MedicineWiley

Published: Apr 1, 2011

There are no references for this article.